Matteo et al. reported the first patient with an extramedullary CNS relapse had response to targeted dabrafenib and trametinib treatment, providing evidence that a point mutation within the capicua transcriptional repressor (CIC) gene mediated the acquired resistance in this patient, which indicated that BRAF mutations might be a promising druggable target in multiple myeloma (Da Vià et al., 2020). The gene discussed is BRAF; the disease is AL amyloidosis.